Quoin Pharma (QNRX) Receives Conditional FDA Acceptance for QYLEKI Brand Name

Quoin Pharma (QNRX) announced on June 23, 2026, that the U.S. Food and Drug Administration (FDA) has conditionally accepted "QYLEKI" as the proposed brand name for its investigational drug candidate, QRX003. This regulatory step is a prerequisite for potential market approval of the treatment. QRX003 is a topical lotion under development for Netherton Syndrome, a rare genetic disorder causing severe skin barrier defects. The conditional acceptance of the brand name signifies the FDA's preliminary approval, which will become final upon the drug's eventual marketing authorization.